IBA - DATA CONCERNING TRANSPARENCY
Louvain-la-Neuve, Belgium, April 1, 2015 - IBA (Ion Beam Applications SA, EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received on February 27, 2015 a transparency notification, in accordance with Article 29 §1 al.2 of the Transparency Law (law of May 2, 2007 and Royal Decree of February 14, 2008), the content of which is summarized below.
Belgian Anchorage SCRL sold, since April 24, 2014, 435 000 IBA shares with voting rights (50 000 shares sold onMarch 26, 2015, 225 000 on March 27, 2015, 75 000 on March 30, 2015 and 85 000 on March 31, 2015). On June 27, 2014, an agreement regarding certification of IBA shares in favour of Belgian Anchorage SCRL and concerning 270 464 shares was terminated.
As a consequence:
- the sum of the shareholdings of Belgian Anchorage SCRL, IBA Investments SCRL and IBA SA, affiliated companies, has gone on March 27, 2015, below the 25% threshold; and
- on March 31, 2015, Belgian Anchorage SCRL only held 6 204 668 IBA shares with voting rights.
The situation as at March 31, 2015 is as follows:
| entity | 24 April 2014 (last transparency notification for Belgian Anchorage) Denominator 27 667 636 | 31 March 2015 Denominator 28 653 520 | Variation | |||
| Shares with voting rights | % | Shares with voting rights | % | Shares with voting rights | % | |
| Belgian Anchorage SCRL | 6 910 132 | 24.98% | 6 204 668 | 21.65% | 705 464 | 3.32% |
| IBA Investment SCRL | 610 852 | 2.21% | 610 852 | 2.13% | 0 | 0.08% |
| IBA SA | 75 637 | 0.27% | 75 637 | 0.26% | 0 | 0.01% |
| Total | 7 596 621 | 27.46% | 6 891 157 | 24.05% | 705 464 | 3.41% |
* * *
*
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
For more information, please contact
IBA
Caroline Hardy
Corporate Legal Counsel
+32 10 201 159
caroline.hardy@iba-group.com
